Trial Profile
An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naive Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Darunavir; Ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- 25 Mar 2020 Results assessing long-term 5-years follow-up, published in the Journal of Antimicrobial Chemotherapy
- 11 Mar 2020 Results (n=114) assessing impact of antiretroviral therapy initiation on epigenetic aging and telomere length, presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 07 Mar 2019 Results assessing effect of UGT1A1 polymorphisms on raltegravir PK/PD (n=349) presented at the 26th Conference on Retroviruses and Opportunistic Infections.